Lindbrook Capital LLC Boosts Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Lindbrook Capital LLC raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 247.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,740 shares of the medical device company’s stock after purchasing an additional 1,239 shares during the period. Lindbrook Capital LLC’s holdings in DexCom were worth $135,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Versant Capital Management Inc purchased a new stake in shares of DexCom during the fourth quarter worth about $25,000. Private Trust Co. NA grew its stake in shares of DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after acquiring an additional 245 shares during the last quarter. Heck Capital Advisors LLC purchased a new stake in shares of DexCom during the fourth quarter worth about $38,000. SBI Securities Co. Ltd. purchased a new stake in shares of DexCom during the fourth quarter worth about $49,000. Finally, Midwest Capital Advisors LLC purchased a new stake in shares of DexCom during the fourth quarter worth about $54,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Trading Down 2.1 %

Shares of NASDAQ:DXCM opened at $77.84 on Friday. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $30.42 billion, a PE ratio of 54.43, a PEG ratio of 2.30 and a beta of 1.28. The business has a 50 day moving average of $84.83 and a two-hundred day moving average of $76.96. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Transactions at DexCom

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This represents a 2.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares of the company’s stock, valued at $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,083 shares of company stock valued at $3,309,794 in the last three months. 0.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on DXCM. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Citigroup upped their target price on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Tuesday. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Finally, Morgan Stanley upped their target price on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $99.82.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.